Incyte (NASDAQ:INCY) Stock Gets Price Target Reduction from Leerink Partners

Incyte (NASDAQ:INCY) had its target price decreased by Leerink Partners from $154.00 to $150.00 in a research note published on Thursday morning,Benzinga reports. Leerink Partners currently has an outperform rating on the biopharmaceutical company’s stock.

A number of other research analysts have also commented on the company. Stifel Nicolaus increased their price objective on Incyte from $145.00 to $157.00 and gave the company a “buy” rating in a report on Monday, October 5th. BMO Capital Markets restated a “market perform” rating on shares of Incyte in a report on Tuesday, October 27th. Weiss Ratings lowered Incyte from a “buy (b+)” rating to a “buy (b)” rating in a report on Friday, October 23rd. Citigroup reaffirmed a “buy” rating on shares of Incyte in a research report on Monday, August 3rd. Finally, Wells Fargo & Company lowered their price target on Incyte from $128.00 to $127.00 and set an “equal weight” rating on the stock in a report on Friday, October 30th. Twelve research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Incyte currently has a consensus rating of “Hold” and an average price target of $132.86.

Incyte Trading Up 1.4%

Shares of NASDAQ:INCY opened at $119.65 on Thursday. The stock has a market capitalization of $24.39 billion, a PE ratio of 63.64, a P/E/G ratio of 4.36 and a beta of 0.78. Incyte has a 1 year low of $89.25 and a 1 year high of $132.60. The firm has a fifty day moving average price of $119.62 and a 200 day moving average price of $108.51.

Incyte (NASDAQ:INCY) last posted its earnings results on Thursday, October 29th. The biopharmaceutical company reported ($3.60) EPS for the quarter, topping the consensus estimate of ($3.93) by $0.33. Incyte had a net margin of 6.71% and a return on equity of 7.92%. The firm had revenue of $1.56 billion for the quarter, compared to the consensus estimate of $1.46 billion. During the same period in the prior year, the business posted $2.26 earnings per share. The business’s quarterly revenue was up 14.0% on a year-over-year basis. On average, sell-side analysts forecast that Incyte will post 2.24 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Pablo J. Cagnoni sold 2,642 shares of the stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $112.71, for a total transaction of $297,779.82. Following the completion of the sale, the insider owned 183,200 shares in the company, valued at $20,648,472. This represents a 1.42% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Thomas Tray sold 610 shares of the stock in a transaction that occurred on Tuesday, November 3rd. The shares were sold at an average price of $118.96, for a total value of $72,565.60. Following the sale, the insider owned 21,126 shares of the company’s stock, valued at approximately $2,513,148.96. The trade was a 2.81% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 14,053 shares of company stock worth $1,726,519. 16.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Greenleaf Trust raised its position in Incyte by 2.8% during the second quarter. Greenleaf Trust now owns 3,358 shares of the biopharmaceutical company’s stock valued at $381,000 after acquiring an additional 93 shares in the last quarter. Parallel Advisors LLC lifted its stake in Incyte by 2.4% in the third quarter. Parallel Advisors LLC now owns 5,082 shares of the biopharmaceutical company’s stock valued at $617,000 after acquiring an additional 121 shares during the last quarter. 180 Wealth Advisors LLC grew its position in Incyte by 2.0% in the first quarter. 180 Wealth Advisors LLC now owns 6,877 shares of the biopharmaceutical company’s stock worth $647,000 after acquiring an additional 132 shares in the last quarter. Mather Group LLC. grew its position in Incyte by 13.5% in the third quarter. Mather Group LLC. now owns 1,157 shares of the biopharmaceutical company’s stock worth $140,000 after acquiring an additional 138 shares in the last quarter. Finally, Tema ETFs LLC grew its position in Incyte by 5.7% in the second quarter. Tema ETFs LLC now owns 2,704 shares of the biopharmaceutical company’s stock worth $307,000 after acquiring an additional 145 shares in the last quarter. 96.97% of the stock is currently owned by institutional investors and hedge funds.

Key Incyte News

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Leerink Partners reaffirmed its Buy rating and set a $150 price target, indicating confidence in Incyte’s prospects. Article
• Positive Sentiment: Incyte plans to present new hematology data at ASH 2026. Canaccord Genuity maintained its Buy rating and $152 target, citing upcoming data for ’989 as support for its view; the results could provide updates on pipeline potential. Article Analyst report
• Neutral Sentiment: Incyte raised Bernstein’s price target to $108 from $104. The increase is modest, and the new target remains below the recent share price. Article
• Neutral Sentiment: The company awarded grants supporting projects focused on graft-versus-host disease (GVHD). The program underscores its engagement in the area but is unlikely to materially affect near-term revenue. Article
• Neutral Sentiment: Insider Thomas Tray sold 610 shares under a pre-arranged Rule 10b5-1 plan, retaining more than 21,000 shares afterward. The planned, relatively small sale offers limited directional signal. Article

About Incyte

Incyte is a biopharmaceutical company that discovers, develops and commercializes medicines, with a focus on oncology, hematology and inflammatory and autoimmune diseases. Founded in 1991, the company is headquartered in Wilmington, Delaware, and conducts research and commercial activities in the United States and internationally.

Its products include Jakafi (ruxolitinib), used to treat certain blood disorders and graft-versus-host disease, and Opzelura (ruxolitinib cream), approved in the United States for certain skin conditions.